VBL Therapeutics to Present Positive Phase 1/2 Data for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
VBL Therapeutics to Present Positive Phase 1/2 Data for VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO Annual Meeting

TEL AVIV, Israel, May 13, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that principal investigator, Richard Penson, M.D., M.R.C.P., will present interim data from the ongoing Phase 1/2 clinical trial of lead product candidate, VB-111, for the treatment of platinum-resistant Müllerian cancer, in a poster presentation on Saturday, May 30, 2015 at the American Society for Clinical Oncology (ASCO) 2015 Annual Meeting. The reported data will include results in patients with recurrent platinum-resistant Müllerian cancer treated with multiple doses of VB-111 and weekly paclitaxel.

As the first highly targeted anti-angiogenic agent for the specific inhibition of tumor vascular growth to use VBL's Vascular Targeting System™ for cancer therapy, VB-111 has the potential to treat a range of solid tumor indications by selectively targeting the blood vessels required for tumor growth and inducing apoptosis of cells in those blood vessels. VBL recently reported positive, statistically significant data evaluating the efficacy of VB-111 for the treatment of recurrent glioblastoma (rGBM), and expects to initiate a pivotal Phase 3 study in rGBM under a Special Protocol Assessment with the U.S. Food and Drug Administration in mid-2015.

Details of the presentation are as follows:

Abstract: #5542
Title: A phase 1/2 trial of multiple dose VB-111 and weekly paclitaxel in recurrent
  platinum-resistant Müllerian cancer
Time: Saturday, May 30, 2015, 1:15 PM – 4:45 PM CT
Session: Poster Session: Gynecologic Cancer
Authors: Richard T Penson MD MRCP (Massachusetts General Hospital), Allison J Ambrosio BA 
  (Massachusetts General Hospital), Daphne Suzin BA BSc (Massachusetts General 
  Hospital), Siobhan A. Collins BA (Dana Farber Cancer Institute), Michael J Birrer 
  PhD (Massachusetts General Hospital), Suzanne Berlin DO (Dana Farber Cancer 
  Institute), Yael Cohen MD (VBL Therapeutics).

About VB-111:

VB-111 is a novel, intravenously-administered, anti-angiogenic agent that utilizes VBL's proprietary Vascular Targeting System (VTS™) to target endothelial cells in the tumor vasculature for cancer therapy. VB-111 contains a non-replicating adenovector, a proprietary modified murine pre-proendothelin promoter (PPE-1-3x) and a Fas-Chimera transgene to angiogenic tumor blood vessels, leading to their apoptosis. VB-111 is the first agent based on transcriptional targeting of tumor endothelium to be assessed in a clinical trial.

VB-111 completed a Phase 1/2 "all-comers" clinical trial, which demonstrated multiple cases of objective tumor response and disease control and excellent safety and tolerability. VB-111 has Fast Track Designation for recurrent glioblastoma in the US and organ drug status for glioblastoma in both the US and EU. VBL is conducting early phase II studies in thyroid and ovarian cancer.

About VBL :

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 clinical trial of VB-111 in rGBM in mid-2015, under a special protocol assessment agreement granted by the FDA.

Forward Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200,

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 48

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 117

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 56

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 79

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 382

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 59

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 87

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Voices: Chicago's Latina Trailblazers Unite

Updated Category News Views 156

Empowering Voices: Chicago's Latina Trailblazers Unite The Chicago History Museum is set to host a remarkable celebration of the book, Chicago Latina Trailblazers. This event recognizes the contributions of remarkable Latina leaders through compelling narratives of activism and community service. Event Overview On a significant date that marks a celebration of Latina...

Continue Reading
Mark Green to Keynote CyberScape Summit Focused on Cybersecurity

Updated Category News Views 132

Mark Green to Keynote CyberScape Summit U.S. House Homeland Security Committee Chairman Mark Green is set to showcase his insights as the keynote speaker for GovCIO Media & Research's CyberScape Summit. The event promises to be an essential gathering for those interested in advancing cybersecurity practices and policies within the government. Focus on Cybersecurity and...

Continue Reading
Brian D. Pieninck Takes Leadership Role at GuideWell

Updated Category News Views 539

Brian D. Pieninck Assumes Role as GuideWell President & CEO GuideWell Mutual Holding Corporation has recently made a significant executive decision by appointing Brian D. Pieninck as the new president and chief executive officer (CEO), effective October 1. Previously, Pieninck served as the president and CEO of CareFirst BlueCross BlueShield and was the Board Chair for...

Continue Reading
Calidi Biotherapeutics Unveils Promising CLD-401 Data at SITC

Updated Category News Views 175

Calidi Biotherapeutics Showcases CLD-401 at SITC Calidi Biotherapeutics, Inc. (NYSE: CLDI), a clinical-stage biotechnology firm, recently presented impactful new data regarding its lead therapeutic candidate CLD-401 during the Society for Immunotherapy of Cancer (SITC) Annual Meeting. This presentation highlighted the innovative capabilities of Calidi’s RedTail...

Continue Reading
Everlight Solar: Milwaukee's Top Pick for Eco Energy

Updated Category News Views 21

A High Wattage Win for Everlight Solar Milwaukee seems to have found its favorite solar squad, and it’s none other than Everlight Solar, folks. They’ve locked in the 2026 Milwaukee's Top Choice in the Solar Services Company category. Now, that’s a badge you wear with pride when it's handed out by the very community you serve. It's not every day you see a company...

Continue Reading